Compounded vs Brand-Name GLP-1 Medications: What You Need to Know
Compounded GLP-1s cost a fraction of brand-name Wegovy or Zepbound. But are they the same drug? Are they safe? Here's an honest breakdown of what's identical, what's different, and how to make an informed decision.
What Are Compounded Medications?
Compounded medications are custom-prepared formulations made by pharmacies outside of the standard drug manufacturing process. A compounding pharmacy takes a pharmaceutical ingredient and prepares it into a specific formulation — a particular dose, delivery method, or combination — for individual patients or in bulk.
Compounding is legal under U.S. federal law, but the regulatory framework depends heavily on which type of pharmacy is doing the compounding and under what circumstances.
Key distinction: Compounded semaglutide or tirzepatide is not the same as counterfeit or illegal drugs. Compounding is a legitimate, FDA-regulated practice with a long history in U.S. pharmacy. The nuances — and the risks — are in the details.
503A vs 503B Pharmacies: Why This Matters
Not all compounding pharmacies operate under the same rules. There are two categories under federal law, and understanding the difference is critical when evaluating the safety of compounded GLP-1s.
503A Pharmacies
- Prepare individual prescriptions for specific patients
- Regulated primarily by state pharmacy boards
- Not required to register with the FDA
- May have more variable quality control standards
- Can only compound when there is a patient-specific prescription
503B Outsourcing Facilities
- FDA-registered outsourcing facilities
- Can produce drugs in bulk (not just individual prescriptions)
- Subject to FDA inspections and Current Good Manufacturing Practice (cGMP) standards
- Required to report adverse events to the FDA
- Generally considered significantly safer and more consistent
Bottom line on pharmacies:If you're considering compounded GLP-1s, prioritize pharmacies that compound through or source from 503B-registered outsourcing facilities. Most reputable telehealth platforms that offer compounded semaglutide or tirzepatide use 503B-registered facilities.
What's the Same
There are meaningful similarities between compounded and brand-name GLP-1 products that are important to understand:
What's Different
This is where the honest complexity lives. There are real differences that anyone considering compounded GLP-1s should understand:
Not FDA-approved as a finished product
The FDA approves drugs as finished products — specific formulations, manufacturers, and processes. Compounded semaglutide uses FDA-approved pharmaceutical-grade semaglutide as an ingredient, but the compounded formulation itself is not FDA-approved. This is the foundational regulatory difference.
Semaglutide sodium salt vs semaglutide base
Some compounded products use semaglutide sodium salt rather than the semaglutide free base used in Wegovy and Ozempic. The FDA has issued warnings noting that semaglutide sodium is not the same active ingredient as semaglutide base — the salt form may have different bioavailability. Reputable 503B facilities are increasingly moving to semaglutide base, but it's worth confirming which form your pharmacy uses.
No large-scale clinical trials on compounded formulations
The clinical trial data behind semaglutide — the STEP trials showing ~15–21% weight loss — was conducted using the brand-name formulation. There are no Phase 3 trials specifically on compounded semaglutide. The assumption that outcomes are identical is reasonable based on pharmacology, but it remains an assumption, not proven data.
Different inactive ingredients and preservatives
Compounded formulations may use different buffers, preservatives, or stabilizers than the brand-name versions. This is typically not clinically significant, but it can affect stability, tolerability, and shelf life. It also means the products aren't interchangeable in a technical sense.
No manufacturer patient assistance programs
Novo Nordisk and Eli Lilly offer patient savings programs that can reduce cost significantly for eligible patients. These programs only apply to brand-name Wegovy, Ozempic, Zepbound, and Mounjaro — not to compounded versions.
Which peptide is right for you?
Get our free comparison chart — trial data, dosing, costs, side by side.
The Safety Question
The FDA has raised legitimate safety concerns about some compounded GLP-1 products — and it's important to understand what those concerns are specifically, rather than treating them as a blanket condemnation of all compounded GLP-1s.
What the FDA Has Said
- The FDA has warned about products using semaglutide sodium salt, which is not the approved active form.
- The FDA has taken action against facilities producing compounded semaglutide that did not comply with compounding regulations.
- The FDA explicitly stated that semaglutide is no longer on the drug shortage list (as of early 2025), which affects the legal basis for 503A compounding — though 503B facilities may still compound under certain conditions.
- The FDA has not issued a blanket ban on all compounded semaglutide or tirzepatide.
How to Verify a 503B Pharmacy
The FDA maintains a public list of registered 503B outsourcing facilities. Before purchasing compounded GLP-1s, you can verify your pharmacy or the facility it sources from at the FDA's official 503B registered outsourcing facilities database.
Red Flags to Watch For
No prescription required
Legitimate compounded medications require a prescription. No prescription = not legally compounded.
Claims to be 'FDA-approved'
Compounded medications cannot be FDA-approved as finished products. This claim is false.
Unusually low price without a telehealth consultation
May indicate the product is coming from an unregulated source.
Unable to name or verify the compounding facility
Reputable providers can tell you exactly which 503B facility their product comes from.
Semaglutide sodium salt not disclosed
Ask explicitly whether the product uses semaglutide base or sodium salt.
The Cost Comparison
The cost gap between brand-name and compounded GLP-1s is the primary reason people consider compounding. Here's what you're actually looking at:
| Medication | Type | Monthly Cost |
|---|---|---|
| Wegovy (semaglutide) | Brand-name | ~$1,350/mo |
| Zepbound (tirzepatide) | Brand-name | ~$1,069/mo |
| Compounded semaglutide | Compounded (503B) | $149–$299/mo |
| Compounded tirzepatide | Compounded (503B) | $249–$349/mo |
Brand-name prices reflect list price without insurance or savings programs. With a good insurance plan, brand-name costs can drop significantly. With manufacturer savings programs (for those without insurance or with high-deductible plans), Wegovy can be as low as $650–$900/mo for some patients.
Who Should Consider Compounded GLP-1s
For many people, the calculus is straightforward: brand-name at $1,350/month is not accessible. Compounded at $200/month, from a verified 503B facility, with a prescription from a licensed provider, is a clinically reasonable alternative. The imperfect option is often better than no option.
Who Should Stick with Brand-Name
The Bottom Line
Compounded GLP-1 medications are not the same as brand-name products — but they're also not inherently dangerous or fraudulent when obtained from a reputable source. The key distinctions:
The right choice depends on your access to insurance, your budget, your comfort with the regulatory nuances, and what your provider recommends. Both pathways can lead to the same clinical outcomes — the evidence just comes with more certainty for brand-name products.
We'll update this article as the FDA's position on compounded GLP-1s evolves.
Sources
- FDA. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” FDA.gov. 2024.
- FDA. “503B Outsourcing Facilities.” FDA.gov. Updated 2025.
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” N Engl J Med. 2021;384:989–1002.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” N Engl J Med. 2022;387:205–216.
- FDA. “Shortage of Semaglutide.” Drug Shortage Database. 2024–2025.
Educational content only. This does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any medication. PeptidePub is an independent publication and does not endorse any specific compounding pharmacy or telehealth provider.